Business Description
3D Medicines Inc
ISIN : KYG8872R1011
Compare
Compare
Traded in other countries / regions
01244.Hong Kong IPO Date
2022-12-15Description
3D Medicines Inc is a commercial-stage biopharmaceutical company that researches, develops, and commercialization of drugs in the field of managing cancer as a chronic disease. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.53 | |||||
| Equity-to-Asset | 0.66 | |||||
| Debt-to-Equity | 0.3 | |||||
| Debt-to-EBITDA | -0.52 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 1.49 | |||||
| Beneish M-Score | 1.12 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 88.99 | |||||
| 9-Day RSI | 72.7 | |||||
| 14-Day RSI | 62.31 | |||||
| 6-1 Month Momentum % | -24.44 | |||||
| 12-1 Month Momentum % | -91.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.19 | |||||
| Quick Ratio | 2.18 | |||||
| Cash Ratio | 1.99 | |||||
| Days Inventory | 33.91 | |||||
| Days Sales Outstanding | 41.67 | |||||
| Days Payable | 325.37 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -33.43 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 92.27 | |||||
| Operating Margin % | -66.37 | |||||
| Net Margin % | -82.64 | |||||
| FCF Margin % | -64.21 | |||||
| ROE % | -56.72 | |||||
| ROA % | -38.07 | |||||
| ROIC % | -86.96 | |||||
| ROC (Joel Greenblatt) % | -288 | |||||
| ROCE % | -58.87 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.13 | |||||
| PB Ratio | 1.62 | |||||
| Price-to-Tangible-Book | 1.62 | |||||
| EV-to-EBIT | -1.37 | |||||
| EV-to-EBITDA | -1.41 | |||||
| EV-to-Revenue | 1.2 | |||||
| EV-to-FCF | -1.87 | |||||
| Price-to-Net-Current-Asset-Value | 2.53 | |||||
| Price-to-Net-Cash | 3.01 | |||||
| Earnings Yield (Greenblatt) % | -72.99 | |||||
| FCF Yield % | -26.78 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
3D Medicines Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 694.495 | ||
| EPS (TTM) (HK$) | -2.516 | ||
| Beta | 0 | ||
| Volatility % | 88.87 | ||
| 14-Day RSI | 62.31 | ||
| 14-Day ATR (HK$) | 0.389302 | ||
| 20-Day SMA (HK$) | 5.7665 | ||
| 12-1 Month Momentum % | -91.36 | ||
| 52-Week Range (HK$) | 4.68 - 131.5 | ||
| Shares Outstanding (Mil) | 258.18 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
3D Medicines Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
3D Medicines Inc Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
3D Medicines Inc Frequently Asked Questions
What is 3D Medicines Inc(HKSE:01244)'s stock price today?
The current price of HKSE:01244 is HK$6.45. The 52 week high of HKSE:01244 is HK$131.50 and 52 week low is HK$4.68.
When is next earnings date of 3D Medicines Inc(HKSE:01244)?
The next earnings date of 3D Medicines Inc(HKSE:01244) is .
Does 3D Medicines Inc(HKSE:01244) pay dividends? If so, how much?
3D Medicines Inc(HKSE:01244) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers